Intelligence Profile
Research Papers
The available research on TB-500 (Thymosin Beta-4 Fragment) is limited, with most studies focusing on characterization rather than clinical efficacy.
A 2012 study in Drug Testing and Analysis (PMID: 22962027) focused on the synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta-4, which is the active component found in TB-500. This research was conducted primarily to understand the compound's structure for anti-doping purposes, noting TB-500's "suspected doping potential" rather than evaluating therapeutic benefits.
A more recent 2026 review in Sports Medicine (PMID: 41966639) examined the safety and efficacy of various peptide therapies, including TB-500, for musculoskeletal injuries and athletic performance enhancement. However, specific study designs, sample sizes, and detailed findings for TB-500 are not provided in the available evidence.
Clinical Trials
Currently, there is one active clinical trial investigating TB-500:
NCT07487363 is a Phase 1/2 trial examining TB-500 for cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). The trial is currently recruiting participants, but sample size, specific endpoints, and preliminary results are not available in the provided evidence.
Evidence Limitations
The research evidence for TB-500 is notably sparse. Most available studies focus on the compound's chemical characterization rather than clinical outcomes. The therapeutic applications being investigated appear to span from musculoskeletal injuries to cardiovascular conditions, but robust clinical data demonstrating safety and efficacy is lacking in the current literature.
This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider before considering any experimental therapies.